Teva's UZEDY® Sales Surge 43% YoY; Medincell Royalties and Milestones in Focus
Event summary
- UZEDY® U.S. net sales hit $77M in Q2 2026, up 43% YoY.
- Teva raised its 2026 revenue outlook for UZEDY® to $270M–$290M from $250M–$280M.
- U.S. prescriptions for UZEDY® increased 63% YoY, with over 800 new prescribers added monthly.
- Medincell eligible for up to $105M in commercial milestone payments tied to sales thresholds.
The big picture
Medincell’s BEPO® technology is proving its market viability through Teva’s UZEDY® success, positioning it as a key player in long-acting injectables for mental health. The 43% YoY sales surge underscores growing demand for adherence-friendly treatments, while pending regulatory decisions could further solidify Medincell’s commercial pipeline.
What we're watching
- Regulatory Approval
- Whether Teva’s once-monthly olanzapine LAI secures FDA approval in Q4 2026, expanding Medincell’s pipeline.
- Market Penetration
- The pace at which UZEDY® gains prescriber adoption beyond schizophrenia into Bipolar I Disorder.
- Revenue Milestones
- How quickly UZEDY® sales hit thresholds triggering Medincell’s $105M in commercial milestone payments.